GSK pitches new growth to investors post consumer healthcare split

GSK is hoping a return to growth, albeit at a 3% annualized rate through 2031, is enough to satiate investors who will see their dividend slashed by 31% following the split of GSK’s biopharma and consumer healthcare businesses next year.

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) spelled out its plans for the split on Wednesday, confirming it’s going ahead with the breakup in mid-2022, and signaled the potential for an uptick in BD activities, including bolt-on deals...